Get more information on Personalized Medicine Market - Request Sample Report
The Personalized Medicine Market was valued at USD 530.01 billion in 2023, and is expected to reach USD 1,078.17 billion by 2032, and grow at a CAGR of 8.21% over the forecast period 2024-2032.
The healthcare landscape is undergoing a seismic shift, driven by a growing consumer demand for personalized care. This, coupled with a growing distrust of traditional healthcare systems, is fueling a surge in self-service health solutions. According to Abbott Research which indicates a strong patient desire for tailored healthcare at 72% of respondents expressed a need for treatment plans that directly address their specific health conditions and data.
Personalized medicine is increasingly demanded across a spectrum of medical conditions. The unique biological makeup of each individual necessitates tailored treatments. Chronic diseases like diabetes highlight this need, as blood sugar control and medication efficacy vary widely. Cancer treatment, too, requires a personalized approach, given the diverse genetic makeup of tumors and patient responses to therapies. Mental health conditions also underscore the importance of individualized care, as symptoms and treatment responses differ significantly between patients. According to the World Health Organization, the number of people living with diabetes skyrocketed from 108 million in 1980 to a staggering 422 million in 2024. This alarming increase is particularly pronounced in low and middle-income countries, underscoring the urgent need for global health interventions.
Meeting this demand for personalized medicines presents significant challenges. Developing treatments tailored to specific genetic profiles, lifestyle factors, and disease variations requires substantial research and development investment. Additionally, ensuring equitable access to these advanced therapies is a complex issue that requires careful consideration of cost, distribution and healthcare infrastructure.
The supply of personalized medicines is currently in its infancy. While the potential benefits are immense, significant hurdles, remain. Developing these treatments is a complex and costly endeavor, requiring substantial investments in research and development. Additionally, manufacturing personalized medicines on a large scale presents logistical challenges. Ensuring equitable access to these therapies is another critical issue. Factors such as cost, infrastructure, and healthcare disparities can hinder the widespread availability of personalized medicine, particularly in low and middle-income countries. Despite these challenges, ongoing advancements in technology and increasing recognition of the potential benefits are driving progress in this field.
ClinicalTrials.gov reveals a promising development i.e. 42 ongoing phase 3 and 4 trials dedicated to personalized medicine. These later-stage trials aim to confirm the safety and efficacy of these tailored treatments.
Government initiatives and regulatory frameworks are pivotal in driving the development and adoption of personalized medicine. To foster innovation, many countries are investing in research and development, offering tax incentives, and creating public-private partnerships. For instance, the Precision Medicine Initiative in the United States has spurred significant advancements. On the regulatory front, agencies like the FDA are adapting guidelines to accommodate the unique challenges of personalized medicine, focusing on real-world evidence and patient-centric outcomes. However, balancing innovation with patient safety and ensuring equitable access remain key challenges. The FDA has also approved numerous personalized medicines, especially in cancer treatment, using genetic markers and diagnostic tests to match patients with optimal therapies.
Overall, personalized medicine holds immense potential to revolutionize healthcare. It is poised to become a cornerstone of future medical practices.
MARKET DYNAMICS
Drivers
The Convergence of Genomics, AI, and Patient-Centric Care in the Personalized Medicine Market
The personalized medicine market is undergoing a transformative evolution, driven by a complex interplay of scientific advancements, evolving healthcare paradigms, and supportive regulatory environments. At the forefront are groundbreaking developments in genomics and biotechnology, which have unlocked the human genetic code and paved the way for precision medicine. By identifying specific genetic markers associated with diseases, researchers and clinicians can now develop targeted therapies tailored to individual patients, offering the promise of more effective and less toxic treatments. The rising prevalence of chronic diseases, such as diabetes, heart disease, and cancer, has amplified the need for personalized approaches. These conditions often exhibit significant patient-to-patient variability, making traditional one-size-fits-all treatments less effective. Personalized medicine offers the potential to optimize treatment plans, improve patient outcomes, and enhance quality of life. Furthermore, a growing emphasis on patient-centric care has aligned perfectly with the goals of personalized medicine. By involving patients in treatment decisions and tailoring care to their individual needs and preferences, healthcare providers can foster stronger therapeutic relationships and improve adherence to treatment regimens.
Technological advancements, particularly in artificial intelligence, big data analytics, and digital health, are accelerating the development and implementation of personalized medicine. These tools enable the analysis of vast amounts of patient data, including genetic, clinical, and lifestyle information, to identify patterns and inform treatment decisions. Additionally, digital platforms facilitate remote monitoring, patient engagement, and the delivery of personalized interventions.
Lastly, supportive government policies and investments are essential for the growth of the personalized medicine market. By providing funding for research, developing regulatory frameworks, and incentivizing innovation, governments can accelerate the development and adoption of personalized therapies.
These converging factors are collectively driving the personalized medicine market towards a future where healthcare is more precise, effective, and patient-centered.
Restraints
High Costs
The development and implementation of personalized treatments can be prohibitively expensive, limiting accessibility for many patients.
Data Privacy and Security Concerns
Handling sensitive genetic and health data requires robust security measures, which can be complex and costly to implement.
Lack of Standardization
The absence of standardized data formats and analytical tools can hinder the integration and analysis of patient data.
By Product
Personalized nutrition and wellness segment held a dominated 32.57% share of the personalized medicine market. This segment is experiencing rapid growth due to increasing consumer interest in tailored health solutions and favorable regulatory conditions. Conversely, the personalized medicine therapeutics segment is projected to be the fastest-growing sector in the market, with a robust CAGR anticipated from 2024 to 2032. Advancements in genomics and decreasing sequencing costs are the primary drivers of this accelerated growth.
By End-use
Hospitals dominated the personalized medicine market in 2023 with 68.2% share, capturing the largest revenue share. This sector's influence is substantial as hospitals serve as both primary consumers and key drivers of personalized medicine adoption. The increasing integration of genomic diagnostics and targeted therapies within hospital settings is accelerating market growth. As early adopters of personalized medicine, hospitals are significantly influencing the development of new diagnostic tools and therapeutic approaches, ultimately shaping the future of this transformative healthcare field.
Regional Analysis
North America dominated the market with 43.02% in 2023, driven by substantial investments in research and development by pharmaceutical giants and research institutions. The region's advanced diagnostic capabilities, exemplified by innovations like Illumina's TruSight Oncology 500 assay, are fueling market expansion.
Europe is another key player, with Germany, the UK, and France at the forefront. These countries are witnessing significant growth due to a combination of research initiatives, government support, and the development of companion diagnostics.
Meanwhile, the Asia Pacific region is emerging as a rapidly growing market, propelled by increasing healthcare expenditure, infrastructure development, and strategic partnerships. China, in particular, is poised for substantial growth due to government support and a growing focus on preventive healthcare.
Need any customization research on Personalized Medicine Market - Enquiry Now
The major key players are GE Healthcare, Illumina, Inc., ASURAGEN, INC., Abbott, Dako A/S, Exact Sciences Corporation, Danaher Corporation (Cepheid, Inc.), Decode Genetics, Inc., QIAGEN, Exagen Inc., Precision Biologics, Celera Diagnostics LLC., Biogen, Genelex, Genentech, Inc., 23andMe, Inc., and Others.
Viome Life Sciences made a strategic move in November 2023 by acquiring Naring Health. This acquisition strengthened Viome's position in personalized nutrition and wellness by incorporating advanced health monitoring capabilities.
| Report Attributes | Details |
| Market Size in 2023 | US$ 530.01 Bn |
| Market Size by 2032 | US$ 1078.17 Bn |
| CAGR | CAGR of 8.21% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics) • By End User (Hospitals, Diagnostic Centers, Research & Academic Institutes, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | GE Healthcare, Illumina, Inc., ASURAGEN, INC., Abbott, Dako A/S, Exact Sciences Corporation, Danaher Corporation (Cepheid, Inc.), Decode Genetics, Inc., QIAGEN, Exagen Inc., Precision Biologics, Celera Diagnostics LLC., Biogen, Genelex, Genentech, Inc., 23andMe, Inc. |
| Key Drivers | • The Convergence of Genomics, AI, and Patient-Centric Care in the Personalized Medicine Market |
| Market Opportunities | • High Costs • Data Privacy and Security Concerns • Lack of Standardization |
Ans: North America segment is expected to held the highest market share in 2023.
Ans: personalized medicine market is anticipated to expand by 8.21% from 2024 to 2032.
Ans: The growth rate of personalized medicine market is expected to grow USD 1078.17 billion by 2032.
Ans: personalized medicine market size was valued at USD 530.01 billion in 2023.
Ans: High cost of customized pharmaceuticals.
Table of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Personalized Medicine Market Segmentation, by Product
7.1 Chapter Overview
7.2 Personalized Medicine Diagnostics
7.2.1 Personalized Medicine Diagnostics Market Trends Analysis (2020-2032)
7.2.2 Personalized Medicine Diagnostics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Personalized Medicine Therapeutics
7.3.1 Personalized Medicine Therapeutics Market Trends Analysis (2020-2032)
7.3.2 Personalized Medicine Therapeutics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Personalized Medical Care
7.4.1 Personalized Medical Care Market Trends Analysis (2020-2032)
7.4.2 Personalized Medical Care Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5.1 Personalized Nutrition & Wellness Market Trends Analysis (2020-2032)
7.5.2 Personalized Nutrition & Wellness Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Personalized Medicine Market Segmentation, by End-use
8.1 Chapter Overview
8.2 Hospitals
8.2.1 Hospitals Market Trends Analysis (2020-2032)
8.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Diagnostic Centers
8.3.1 Diagnostic Centers Market Trends Analysis (2020-2032)
8.3.2 Diagnostic Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Research & Academic Institutes
8.4.1 Research & Academic Institutes Market Trends Analysis (2020-2032)
8.4.2 Research & Academic Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Personalized Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.4 North America Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.5.2 USA Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.6.2 Canada Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.7.2 Mexico Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Personalized Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.5.2 Poland Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.6.2 Romania Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Personalized Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.4 Western Europe Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.5.2 Germany Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.6.2 France Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.7.2 UK Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.8.2 Italy Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.9.2 Spain Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.12.2 Austria Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Personalized Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.4 Asia Pacific Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 China Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 India Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 Japan Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.6.2 South Korea Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.7.2 Vietnam Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.8.2 Singapore Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.9.2 Australia Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Personalized Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.4 Middle East Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.5.2 UAE Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Personalized Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.4 Africa Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Personalized Medicine Market Estimates and Forecasts, by Component (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Personalized Medicine Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Personalized Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.4 Latin America Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.5.2 Brazil Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.6.2 Argentina Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.7.2 Colombia Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Personalized Medicine Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Personalized Medicine Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10. Company Profiles
10.1 GE Healthcare
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Illumina, Inc.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 ASURAGEN, INC.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Abbott
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Dako A/S
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Exact Sciences Corporation
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Danaher Corporation (Cepheid, Inc.)
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Decode Genetics, Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 QIAGEN
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Exagen Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Product
Personalized Medicine Diagnostics
Genetic Testing
Direct-To-Consumer (DTC) Diagnostics
Esoteric Lab Services
Esoteric Lab Tests
Personalized Medicine Therapeutics
Pharmaceutical
Genomic Medicine
Medical Devices
Personalized Medical Care
Telemedicine
Health Information Technology
Personalized Nutrition & Wellness
Retail Nutrition
Complementary & Alternative Medicine
By End-use
Hospitals
Diagnostic Centers
Research & Academic Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Antibody Production Market size was estimated at USD 14.33 billion in 2023 and is expected to reach USD 36.49 billion by 2032 at a CAGR of 10.95% during the forecast period of 2024-2032.
The Continuous Glucose Monitoring Market Size was valued at USD 4.62 Billion in 2023, and is expected to reach USD 8.82 Billion by 2032, and grow at a CAGR of 7.80%.
The 3D Printing Medical Device Software Market Size was valued at USD 0.07 billion in 2023 and is expected to reach USD 0.22 billion by 2031 and grow at a CAGR of 15.8% over the forecast period 2024-2031.
The Health IT Security Market was valued at USD 15.3 billion in 2023 and is expected to reach USD 53.9 billion by 2032 at a CAGR of 15.04% from 2024 to 2032.
The Electronic Medical Record (EMR) Systems Market size was valued at USD 29.0 billion in 2023 and is projected to reach over USD 42.6 billion by 2032, with a growing CAGR of 4.2% during the forecast period 2024-2032.
The Electrosurgery Market Size was valued at USD 6.50 Billion in 2023 and is expected to reach USD 12.34 Billion by 2032 and grow at a CAGR of 7.76% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
